29 / 38
To Reverse Endocrine resistance
(TREnd) trial: aims
•
To test activity and safety of Palbociclib:
–
as single agent in a moderately pre-treated
population of patients with HR+ and HER2– mBC
–
in combination with the same ET received before
disease progression
Malorni L, et al. ASCO 2017
Primary endpoint:
Clinical Benefit Rate (CBR) (Complete response, Partial
Response, Stable Disease ≥ 24 weeks as per RECIST 1.1)